Anexigen developes novel methods and compositions designed to combat existing and burgeoning antimicrobial threats. Co-investors include Avalon Ventures.
Annexon Biosciences is developing therapeutic products that halt the progression of complement-mediated neurodegeneration. Co-investors include Clarus Ventures, New Enterprise Associates, Novartis, and Stanford University.
Arista MD offers a customized referral management system to meet the needs of primary and specialty care physicians while significantly reducing costs in “inappropriate” referrals. Co-investors include Avalon Ventures.
CareWell Urgent Care
CareWell Urgent Care is establishing and operating urgent care centers in the New England area. Co-investors include CHL Medical Partners.
Cellular Approaches operates a biotechnology company designed to create augmented innate immunity to treat life-threatening diseases. Co-investors include Avalon Ventures.
Flex Pharma is developing novel treatments for muscle cramps and spasms by halting repetitive firing of motor neurons. Co-investors include include Bessemer Venture Partners, Founders Fund, Lightstone Ventures, and Longwood Venture Partners. In January 2015, Flex Pharma went public (NASDAQ: FLKS).
Future Family provides reproductive healthcare services intended to offer women and couples comprehensive fertility testing and support. Co-investors include Montage Ventures.
Galera Therapeutics is developing biopharmaceuticals targeting oxygen metabolic pathways to treat mucositis, fibrosis, and cancer. Co-investors include New Enterprise Associates, and Novartis Venture Fund. In November 2019 Galera Therapeutics went public (NASDAQ: GRTX).
Gynesonics is a women’s healthcare company focused on minimally invasive solutions for symptomatic uterine fibroids. Co-investors include Abingworth, HBM Partners, and InterWest.
Intervene is a catheter-based technology to create native vein valves in the lower leg to treat severe systems associated with deep vein valve failure. Co-investors include Launch Capital and Rivervest Partners.
Karuna Labs provides a virtual reality based pain and physical therapy platform. Co-investors include Baseline Ventures.
Lemonaid Health is leading a second wave of telehealth where technology algorithms power quality care. Lemonaid leverages evidence-based guidelines and the most up-to-date clinical protocols to offer a service direct to consumer for less than typical co-pays. Lemonaid is focused on creating a revolutionized patient experience and improving and optimizing clinical care through the advancements in machine learning and AI. Co-Investors include Adaptive Healthcare Fund, 415 Ventures, Hikma Ventures, Novartis Venture Fund, and Vega Ventures.
Lexent Bio developes liquid biopsy technology designed to diagnose and treat cancer. Co-investors include Draper Fisher Jurvetson.
Mirna Therapeutics is developing replacement therapy for cancer treatment by harnessing the power of tumor suppressor miRNAs to kill cancer cells. Co-investors include New Enterprise Associates, Pfizer Venture Investments, Soffinova Ventures, and Osage University Partners. In October 2015, Mirna Therapeutics went public. (NASDAQ: MIRN)
ORIC Pharmaceuticals is a developer of novel therapies intended to overcome resistance in cancer. Co-investors include Arromark, Casdin and Invus.
Powervision has developed the FluidVision® intraocular lens implant, designed to restore the vision of those affected by presbyopia and/or cataracts. Co-investors include Aisling Capital, ATV, Frazier Healthcare Ventures, and Venrock. Aquired by Alcon in 2019.
RQx is discovering and developing novel broad-spectrum antibiotics. Co-investors include Avalon Ventures. Acquired by Genetech in 2013.
Gene therapy based pharmaceuticals for veterinary applications. Co-investors include Frazier Healthcare Ventures and Adage Capital.
Spirox is developing a minimally-invasive treatment for nasal valve collapse.Co-investors include Aperture Ventures, Western Technology Investments, and Venrock. Acquired by Entellus Medical (NASDAQ: ENTL)
SynthoRX is advancing the breakthrough technology of synthetic DNA bases that can be replicated in vivo for numerous medical and technological applications. Co-investors include Avalon Ventures. In December 2018, SynthroRX went public (NASDAQ: THOR)and was acquired by Sanofi in 2019.